CN Patent

CN116789648A — 含腈的抗病毒化合物

Assigned to Pfizer Inc · Expires 2023-09-22 · 3y expired

What this patent protects

本发明涉及式I"化合物 其中R、R 1 、R 2 、R 3 、p、q和q’如本文所定义，包含所述化合物的药物组合物，通过给予治疗有效量的所述化合物在患者中治疗冠状病毒感染比如COVID‑19的方法，和用所述化合物抑制或预防冠状病毒比如SARS‑CoV‑2复制的方法。

USPTO Abstract

本发明涉及式I"化合物 其中R、R 1 、R 2 、R 3 、p、q和q’如本文所定义，包含所述化合物的药物组合物，通过给予治疗有效量的所述化合物在患者中治疗冠状病毒感染比如COVID‑19的方法，和用所述化合物抑制或预防冠状病毒比如SARS‑CoV‑2复制的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN116789648A
Jurisdiction
CN
Classification
—
Expires
2023-09-22
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.